BGI Colorectal Cancer Screening (BGI COLOTECT).

BGI Colorectal Cancer Screening (BGI COLOTECT).
Purpose BGI Colorectal Cancer Screening (BGI COLOTECT):

BGI COLOTECT is a Non-Invasive Fecal DNA Test for detecting Colorectal Cancer and precancerous lesions. COLOTECT™ 3.0, a fecal DNA test outperforms fecal immunochemical tests (FIT) in terms of detection of colorectal cancer and advanced precancerous lesions.

“When Colorectal Cancers are detected early, they are highly treatable. If a diagnosis is made when cancer is still highly localized, the overall 5-year survival rate can be around 90%. In contrast, in metastatic colorectal cancer, the 5-year survival rate decreases drastically, to only around 10%”

Who needs to get tested?

Test Code HW2128
Turnaround Time (TAT)10 Days
Sample Tested BGI Colorectal Cancer Screening (BGI COLOTECT):
  • 2-5mL of peripheral blood in EDTA.
Methodology
  • DNA Extraction and QC.
  • It uses multiplex Methylation Specific PCR (MSP) technology to trace abnormal DNA-methylation biomarkers including SDC2, ADHFE1, and PPP2R5C Genes in Colorectal Cancer using Real-time PCR from stool samples. .
  • Reports having information for dysregulated methylation patterns in three genes (SDC2, ADHFE1, and PPP2R5C) pathogenic mutations in baby and detecting a disease at an early stage can enable appropriate and timely medical intervention before more serious and sometimes irreversible health issues are caused.
    Advantages BGI Colorectal Cancer Screening (BGI COLOTECT):
    • Sensitivity for colorectal cancer is greater than 90%.
    • Sensitivity for advanced precancerous lesions is greater than 50%.

    BGI Colorectal Cancer Screening (BGI COLOTECT).

    Download